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Recently, several genome-wide association studies (GWASs) have led to the discovery of
nine new loci of genetic susceptibility in Alzheimer’s disease (AD). However, the landscape
of the AD genetic susceptibility is far away to be complete and in addition to single-SNP
(single-nucleotide polymorphism) analyses as performed in conventional GWAS, complemen-
tary strategies need to be applied to overcome limitations inherent to this type of approaches.
We performed a genome-wide haplotype association (GWHA) study in the EADI1 study
(n=2025 AD cases and 5328 controls) by applying a sliding-windows approach. After
exclusion of loci already known to be involved in AD (APOE, BIN1 and CR1), 91 regions with
suggestive haplotype effects were identified. In a second step, we attempted to replicate
the best suggestive haplotype associations in the GERAD1 consortium (2820 AD cases and
6356 controls) and observed that 9 of them showed nominal association. In a third step,
we tested relevant haplotype associations in a combined analysis of five additional case–
control studies (5093 AD cases and 4061 controls). We consistently replicated the association
of a haplotype within FRMD4A on Chr.10p13 in all the data set analyzed (OR: 1.68; 95% CI:
(1.43–1.96); P=1.1 1010). We finally searched for association between SNPs within
the FRMD4A locus and Ab plasma concentrations in three independent non-demented
populations (n=2579). We reported that polymorphisms were associated with plasma Ab42/
Ab40 ratio (best signal, P=5.4 107). In conclusion, combining both GWHA study and a
conservative three-stage replication approach, we characterised FRMD4A as a new genetic
risk factor of AD.
Molecular Psychiatry (2013) 18, 461–470; doi:10.1038/mp.2012.14; published online 20 March 2012
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Introduction
The identification of genes involved in monogenic
forms of Alzheimer’s disease (AD) has significantly
contributed to our knowledge of the disease mecha-
nisms. The causal links between mutations, the
functions of the mutated genes (APP, PS1 and PS2)
and disease development prompted a pathophysio-
logical hypothesis, which radically changed our
understanding of AD: the amyloid cascade hypo-
thesis.1 The systematic association of pathogenic
mutations with changes in APP metabolism and,
more particularly, a relative overproduction of Ab42
peptides indicates that this metabolism is at the
heart of the disease process (at least in the monogenic
forms of the disease). The overproduction of these
neurotoxic peptides is supposed to lead to or accen-
tuate neuron-to-neuron propagation of the t patho-
logy (leading to neuronal death) by an unknown
mechanism.2
By analogy, it was expected that the characteriza-
tion of genetic factors involved in the common forms
of AD (that is, lacking classical Mendelian inheri-
tance), the most frequent form of the disease, should
also help to better understand the AD physiopatho-
logical process. However, the characterization of these
genetic factors has encountered significant difficul-
ties. Until 2009, the APOE (apolipoprotein E) gene
was the only globally valid genetic determinant of AD
to have been unambiguously identified in 15 years of
intensive research.3,4
As with other multifactorial diseases, this systema-
tic inability to detect new genetic determinants
has prompted more comprehensive investigations
using genome-wide association studies (GWASs).
We and others performed five large GWASs in this
field and reported that the CLU (clusterin), PICALM
(phosphatidylinositol-binding clathrin assembly
protein), CR1 (complement component (3b/4b) recep-
tor 1), BIN1 (bridging integrator 1), ABCA7 (ATP-
binding cassette, sub-family A, member 7), MS4A
(membrane spanning 4A) cluster, EPHA1 (ephrin type-
A receptor 1), CD33 (differentiation antigen 33) and
CD2AP (CD2-associated protein) genes were associated
with the AD risk.5–9 Most of these susceptibility genes
have been already systematically replicated in Cauca-
sians in large case–control studies and in families.10
However, our understanding of the AD genetics
is far away to be complete and strong efforts have still
to be done. At this level, classical GWAS approaches
present an important limitation with systematic
application of a conventional, highly conservative
Bonferroni correction leading to select only the most
statistically significant associations (commonly,
P< 1 108). This involves the risk of rejecting bio-
logically valid hypotheses on purely statistical
grounds, that is, false negatives.
To partly handle some of this limitation, other
complementary approach consists in extracting perti-
nent information from single-nucleotide polymor-
phisms (SNPs) nominally associated with the risk of
developing AD in GWAS by using complex statistical
and bioinformatics multiple-SNP analyses such as
genome-wide haplotype association (GWHA) study.11
We adopted this GWHA strategy to the AD genetic
susceptibility through a three-step approach.
Materials and methods
Population description
The main characteristics of the populations used for
the GWHA study are described in the Supplementary
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Notes and Supplementary Table 1. All AD cases met
the criteria for either probable AD (NINCDS-ADRDA,
DSM-IV)12 or definite AD (CERAD).13 All elderly
controls were screened for dementia using the MMSE
or the AD Assessment Scale-cognitive subscale and
were determined to be free from dementia at neuro-
pathological examination or had a Braak score of 2.5
or below. All subjects or, in those with substantial
cognitive impairment, a caregiver, legal guardian, or
other proxy gave written informed consent for
participation in this study. The study protocols for
all populations were reviewed and approved by the
appropriate Institutional review boards of each
country.
The main characteristics of the populations (non-
demented individuals) used for the Ab plasma study
(3C study, Rotterdam and CHS) are described in the
Supplementary Notes and Supplementary Table 2.14–16
Genotyping
Participants in the French GWA study (including
the 3C study) were genotyped using an Illumina 610–
quad array (Illumina, San Diego, CA, USA). Quality
control and analytical parameters have been de-
scribed in detail elsewhere.5 The GERAD participants
were genotyped using an Illumina 610–quad array
(Illumina), a HumanHap550 array or a HumanHap300
array (Illumina). Again, QC and analytical parameters
have been described in detail elsewhere.6 The
Rotterdam and CHS studies were genotyped using
the Affymetrix 500K array (Affymetrix, Santa Clara,
CA, USA). Again, QC and analytical parameters have
been described in detail elsewhere.7
In the European populations (stage 3), genotyping
was performed using Sequenom assays at the excep-
tion of the German population genotyped with a 610K
ILLUMINA chip (Illumina). The primer and probe
sequences used in the genotyping assays are avail-
able upon request. In order to avoid any genotyping
bias, cases and controls were randomly mixed while
genotyping and laboratory personnel were blinded to
case/control status. The genotyping success rate was
at least 95%. Departure from Hardy–Weinberg equili-
brium was observed for rs2446581 in the Swedish
control and case samples (P= 9.1107 for the whole
population). The Swedish sample was consequently
excluded from further analysis, as haplotype analyses
that do not comply with Hardy–Weinberg equilibrium
are likely to bias observations.
Statistical analyses
Missing age or gender data. Any individuals with
missing age or gender data were excluded. This gave a
maximum of 2025 AD cases and 5328 controls in step
1, 2820 AD cases and 6356 controls in step 2 and 5093
AD cases and 4061 controls in step 3.
Detection of haplotype effects using a sliding-window
approach. This approach has been fully described
elsewhere.11,17 Briefly, the search for haplotype effects
was carried out by applying a sliding-window
approach18,19 to the French GWA data set for each
chromosome. After excluding SNPs not in Hardy–
Weinberg equilibrium or with a minor allele frequency
(MAF) < 0.02, the first step of the strategy was to
eliminate part of the redundancy between SNPs by
using haplotype-tagging SNPs (htSNPs). For this, the
same binning procedure as in11 was used: within each
bin of 10 adjacent SNPs, we identified a minimal set of
htSNPs that were able to characterize more than 95% of
the inferred haplotypes with estimated frequency
greater than 0.02. Once a bin had been characterized
by a set of htSNPs, the same strategy was applied to
the bin composed of the next 10 adjacent SNPs. The
final set of htSNPs (n= 287 956) was then fed into the
sliding-windows approach.
Given a window of 10 htSNPs, the search for
the most informative and parsimonious haplotype
configuration in terms of disease prediction was
performed for all possible 1 to 4 loci combinations
of not necessarily adjacent SNPs. We used a strategy
based on Akaike’s information criterion, which has
been previously described for candidate gene haplo-
type analysis.19,20 It relies on the stochastic expecta-
tion–maximisation module21 in THESIAS software.22
If required, missing genotypes were inferred by
applying,23 multiple imputation.21 In all, 37 330 050
combinations were investigated in our genome scan
and this investigation was conducted thanks to the
use of the grid technology developed by the European
Grid Infrastructure (http://www.egi.eu).20 This tech-
nology enables several thousand computations to be
run in parallel on a large number of different CPUs.
The sliding-window haplotype approach was deve-
loped into a GridHaplo grid package for the EGI grid
(http://genecanvas.ecgene.net).11
Replication of haplotype effects. Regions with
‘window P-values’ (i) below 105 and (ii) 100 times
smaller than the smallest single-locus P-value
(including all SNPs and not only htSNPs) were ana-
lyzed in terms of replication in the GERAD1 data
set by using THESIAS software, with systematic
adjustment for age and gender.
Association of FRMD4A SNPs with Ab plasma
concentrations. In each center, Ab plasma variables
are normally distributed. We excluded prior analyses
all samples with a þ / two s.d. values in order to
avoid potential associations driven by extreme
observations. Finally, each quantitative variable was
transformed into a z-score (equal to (observed value
minus the sample mean), divided by the sample
s.d.). The association between the Ab140, Ab142 and
Ab142/Ab140 z-scores on one hand and imputed
FRMD4A imputed SNPs on the other (see below) were
assessed using a general linear model under an
additive model adjusted for age, center and gender.
We used inverse-variance weighting (also known
as fixed-effects meta-analysis) to investigate the
homogeneity of haplotype effects from one study
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to another and to provide meta-analysed, age- and
gender-adjusted ORs for haplotype effect estimates
in the seven studies. A similar strategy was used to
provide meta-analysed, age- and gender-adjusted
association levels between Ab plasma z-scores and
FRMD4A SNPs.
Imputation analyses
We imputed SNPs by using MaCH (http://www.sph.
umich.edu/csg/abecasis/mach/index.html) and mini-
mac software (http://genome.sph.umich.edu/wiki/
minimac). The reference haplotype data are provided
by the MaCH website, which was built for the
combined Caucasian populations as part of the 1000
genomes project. In our data set, all individuals
were genotyped on the same platform (the Illumina
Human660W-Quad Beadchip) and we used 492 941
observed SNP genotypes that passed quality filters as
follows: genotyping call rateX98%, Hardy–Weinberg
Equilibrium Test P value X1106 and MAF X1%.
We first inferred haplotype combinations of each
individual using the ‘phase’ option in the MaCH
program and then imputed them with minimac. As
minimac is a newly developed software tool, we com-
pared the correlation between the imputed genetic
dosage from minimac and those from the standard
MaCH program for SNPs in chromosome 22. The
results were very similar (data not shown). Doses for
7 704 555 million SNPs with a MAF > 0.01 were avai-
lable from the French GWA data set using the 1000
genomes data set. We selected 2538 SNPs within the
Chromosome 10p13 locus of interest (chromosome10:
13 655 705–14 402 866) and evaluated their associa-
tions with AD risk in an additive logistic regression
model adjusted for age, gender and disease status. A
graphic representation was then generated with Locus-
zoom software (http://csg.sph.umich.edu/locuszoom/).
In the 3C, Rotterdam and CHS cohorts, we used
the genotype data to impute to the 2.5 million
non-monomorphic, autosomal SNPs described in
HapMap II (CEU population) as described elsewhere.7
We selected 1486 SNPs (MAF > 0.01) within the
Chromosome 10p13 locus of interest (chr10:13 655 705–
14 402 866) and evaluated their associations with
Ab plasma concentrations as described above. Again, a
graphic representation was then generated with Locus-
zoom software (http://csg.sph.umich.edu/locuszoom/).
Results
We developed a three-step approach. In the first step,
the French GWA study (EADI1 for European Alzhei-
mer’s initiative 1),5 including 2025 AD cases and 5328
controls was used to select regions with potential
haplotype associations with AD. Following a sliding-
windows approach (see Material and methods), we
applied two a priori criteria to select loci of interest
as previously described:11 level of association with a
P-value (i) below 105 and (ii) at least 100 times
smaller than the smallest single-SNP P value observed
in the corresponding locus. We were able to detect
loci already known to be involved in AD (the APOE,
BIN1 and CR1 locus)5–9 from previous GWASs. The
obtained signal was systematically highly stronger
than the one observed for each SNP taken separately
(Table 1). After exclusion of these loci, we retained 91
regions of interest.
In the second step, we replicated these haplotype
associations in the GWA database from another
consortium involved in the study of AD genetic
susceptibility, the GERAD1 consortium,6 including
2820 AD cases and 6356 controls. All 91 regions were
available for investigation and 9 of them showed
nominal association (P< 0.05; Table 2). We decided
to further investigate two regions showing the same
best haplotypes associated with AD risk in both
EADI1 and GERAD1, with similar magnitude and
direction of association (Table 2). These two loci,
not previously detected in single-SNP GWAS ana-
lyses, were located on chromosomes 6p21 and 10p13.
Table 1 Best haplotype combination observed in CR1, BIN1 and APOE and comparison with the association obtained for
single-SNP analysis within these loci
Locus hTag-SNPs Global haplotype
P-value
Best associated
hTag-SNP
Best associated SNP
within the locus
RS
number
Single P-value
for hTag-SBP
RS
number
P value_single
(CNG)
CR1 rs3818361þ rs1323720þ
rs7527798þ rs2761424
4.12E10 rs3818361 2.6E06 rs3818361 2.6E06
BIN1 rs17014873þ rs749008þ
rs13031703þ rs744373
3.13E09 rs744373 1.04E03 rs10194375 2.4E04
APOE rs157580þ rs8106922þ
rs405509þ rs439401
9.51E184 rs157580 5.4E32 rs2075650 3.32E126
Abbreviations: APOE, apolipoprotein E; BIN1, bridging integrator 1; CR1, complement component (3b/4b) receptor 1;
hTag-SNPs, haplotype-tagging SNPs; SNP, single-nucleotide polymorphism.
Alzheimer’s disease vs GWHA study
J-C Lambert et al
464
Molecular Psychiatry
T
a
b
le
2
L
is
t
o
f
th
e
h
a
p
lo
ty
p
e
c
o
m
b
in
a
ti
o
n
s
id
e
n
ti
fi
e
d
in
th
e
F
re
n
c
h
G
W
A
st
u
d
y
a
n
d
re
p
li
c
a
te
d
a
t
P
<
0
.0
5
in
G
E
R
A
D
C
h
ro
m
o
-
so
m
e
S
N
P
s
u
se
d
in
h
a
p
lo
ty
p
e
s
F
ir
st
p
o
si
ti
o
n
F
in
a
l
p
o
si
ti
o
n
E
A
D
I1
G
E
R
A
D
1
B
e
st
m
e
ta
-a
n
a
ly
se
d
h
a
p
lo
ty
p
e
a
ss
o
c
ia
ti
o
n
B
e
st
h
a
p
lo
ty
p
e
O
R
9
5
%
C
I
B
e
st
h
a
p
lo
ty
p
e
P
v
a
lu
e
G
lo
a
b
l
P
v
a
lu
e
B
e
st
h
a
p
lo
ty
p
e
O
R
9
5
%
C
I
B
e
st
h
a
p
lo
ty
p
e
P
v
a
lu
e
G
lo
a
b
l
P
v
a
lu
e
B
e
st
h
a
p
lo
ty
p
e
O
R
9
5
%
C
I
B
e
st
h
a
p
lo
ty
p
e
P
v
a
lu
e
2
rs
6
7
1
5
9
0
1
þ
rs
2
3
6
6
9
1
3
þ
rs
1
0
4
9
7
5
2
7
þ
rs
1
4
8
9
4
7
9
1
7
9
3
5
9
1
9
9
1
7
9
4
1
6
9
2
2
A
C
G
T
0
.6
9
(0
.5
8
–
0
.8
3
)
4
.3
0
E
0
5
2
.7
7
E
0
6
G
T
G
T
0
.5
6
(0
.3
7
–
0
.8
7
)
9
.4
2
E
0
3
4
.7
0
E
0
2
A
C
G
T
1
.2
3
E
0
3
0
.8
0
(0
.6
9
–
0
.9
1
)
3
rs
6
9
6
2
3
6
þ
rs
7
6
4
1
8
2
1
þ
rs
3
9
1
1
7
7
8
þ
rs
1
4
7
1
3
7
7
6
4
1
8
4
2
5
8
6
4
2
2
8
0
0
8
G
C
C
G
1
.3
3
(1
.1
6
–
1
.5
2
)
2
.8
5
E
0
5
4
.6
5
E
0
6
G
T
C
A
0
.6
8
(0
.5
3
–
0
.8
7
)
2
.3
4
E
0
3
2
.4
3
E
0
2
G
T
C
A
8
.1
5
E
0
3
0
.8
2
(0
.7
1
–
0
.9
5
)
3
rs
8
3
0
6
3
7
þ
rs
7
6
1
2
4
0
7
7
1
7
5
3
1
5
5
7
1
7
6
9
9
9
8
T
A
0
.5
4
(0
.4
1
–
0
.7
1
)
1
.1
3
E
0
5
5
.2
7
E
0
6
T
A
1
.5
0
(1
.0
6
–
2
.1
3
)
2
.3
0
E
0
2
3
.0
4
E
0
2
C
A
3
.5
5
E
0
3
1
.2
5
(1
.0
8
–
1
.4
5
)
4
rs
1
2
6
4
5
9
7
2
þ
rs
1
4
6
6
6
1
4
þ
rs
6
8
1
2
4
1
4
3
7
9
6
6
9
4
1
3
7
9
9
9
2
0
2
T
A
A
1
.4
0
(1
.2
1
–
1
.6
2
)
4
.6
3
E
0
6
9
.3
9
E
0
6
C
A
C
0
.8
2
(0
.7
1
–
0
.9
4
)
4
.3
3
E
0
3
1
.9
0
E
0
2
T
A
A
1
.9
7
E
0
4
1
.2
3
(1
.1
0
–
1
.3
8
)
5
rs
1
1
7
4
0
6
3
2
þ
rs
7
7
2
2
3
7
3
þ
rs
7
7
2
3
3
4
9
þ
rs
6
8
9
3
7
5
2
6
0
1
7
7
0
0
2
6
0
4
1
0
6
6
9
A
A
G
G
1
.1
7
(1
.0
6
–
1
.2
9
)
2
.6
5
E
0
3
8
.8
9
E
0
6
A
A
T
G
0
.8
1
(0
.7
1
–
0
.9
3
)
2
.4
1
E
0
3
1
.5
5
E
0
2
A
A
T
G
1
.2
5
E
0
3
0
.8
7
(0
.8
0
–
0
.9
5
)
6
rs
4
7
1
1
6
5
2
þ
rs
2
3
9
5
7
6
0
þ
rs
9
9
1
7
6
2
4
0
9
6
0
7
1
7
4
1
0
3
1
3
8
8
G
G
T
1
.5
4
(1
.2
7
–
1
.8
7
)
1
.0
2
E
0
5
7
.9
1
E
0
6
G
G
T
1
.5
1
(1
.1
6
–
1
.9
6
)
2
.2
6
E
0
3
1
.1
4
E
0
2
G
G
T
8
.0
8
E
0
8
1
.5
3
(1
.3
1
–
1
.7
9
)
6
rs
1
0
9
4
6
1
5
5
þ
rs
1
9
9
7
6
6
1
þ
rs
9
3
5
5
5
7
8
1
6
6
6
4
4
3
0
2
1
6
6
7
3
9
7
6
4
C
C
T
1
.6
9
(1
.4
1
–
2
.0
2
)
1
.2
6
E
0
8
2
.4
2
E
0
6
T
T
C
1
.4
0
(1
.0
4
–
1
.8
8
)
2
.5
9
E
0
2
4
.8
2
E
0
2
C
C
T
1
.4
1
E
0
7
1
.4
5
(1
.2
6
–
1
.6
6
)
1
0
rs
7
0
8
1
2
0
8
þ
rs
2
4
4
6
5
8
1
þ
rs
1
7
3
1
4
2
2
9
1
4
0
3
1
8
7
1
1
4
0
5
6
1
6
5
A
A
C
1
.8
0
(1
.4
0
–
2
.3
1
)
4
.4
8
E
0
6
4
.0
8
E
0
6
A
A
C
1
.7
1
(1
.2
3
–
2
.3
7
]
1
.3
6
E
0
3
7
.3
9
E
0
3
A
A
C
2
.2
7
E
0
8
1
.7
6
(1
.4
4
–
2
.1
5
)
1
1
rs
7
9
5
0
1
7
1
þ
rs
1
0
8
3
4
8
6
3
þ
rs
2
7
6
9
0
7
þ
rs
2
6
7
2
2
2
1
3
6
6
1
2
8
0
3
7
1
9
7
4
4
T
G
C
T
0
.6
8
(0
.5
9
–
0
.7
7
)
1
.2
1
E
0
8
8
.7
5
E
0
7
T
A
T
T
0
.6
0
[0
.4
7
–
0
.7
6
)
4
.2
7
E
0
5
5
.9
3
E
0
3
T
G
C
T
2
.1
4
E
0
6
0
.7
9
(0
.7
1
–
0
.8
7
)
A
b
b
re
v
ia
ti
o
n
s:
C
I,
c
o
n
fi
d
e
n
c
e
in
te
rv
a
l;
G
W
A
,
g
e
n
o
m
e
-w
id
e
a
ss
o
c
ia
ti
o
n
;
O
R
,
o
d
d
s
ra
ti
o
;
S
N
P,
si
n
g
le
-n
u
c
le
o
ti
d
e
p
o
ly
m
o
rp
h
is
m
.
E
x
a
c
tl
y
re
p
li
c
a
te
d
c
o
m
b
in
a
ti
o
n
s
(i
.e
.,
th
e
sa
m
e
b
e
st
h
a
p
lo
ty
p
e
s
a
ss
o
c
ia
te
d
w
it
h
A
D
ri
sk
in
th
e
d
a
ta
se
ts
fr
o
m
th
e
F
re
n
c
h
G
W
A
st
u
d
y
a
n
d
G
E
R
A
D
,
w
it
h
si
m
il
a
r
m
a
g
n
it
u
d
e
s
o
f
a
ss
o
c
ia
ti
o
n
a
n
d
th
e
sa
m
e
d
ir
e
c
ti
o
n
o
f
a
ss
o
c
ia
ti
o
n
)
a
re
in
d
ic
a
te
d
in
g
ra
y.
Alzheimer’s disease vs GWHA study
J-C Lambert et al
465
Molecular Psychiatry
The identified AD-associated haplotypes at the
6p21 region were tagged by rs2395760, rs991762 and
rs4711652. The rs7081208, rs2446581 and rs17314229
tagged the 10p13 haplotypes. For the Chromosome
6p21 locus, the best association was attributable to
the GGT haplotype in both GWASs (OR (Odds Ratio):
1.53; 95% CI: (1.31–1.79); P= 8.1108 after adjust-
ment for age and gender when both EADI1 and
GERAD1 studies were combined). For the Chromo-
some 10p13 locus, the highest level of association was
attributable to the AAC haplotype (OR: 1.76; 95% CI:
(1.44–2.15); P= 2.3 108 after adjustment for age and
gender when both EADI1 and GERAD1 studies were
combined. Additional adjustment for the four main
principal components did not modify the results, data
not shown) (Table 2).
In the third step, the six tagging SNPs were further
genotyped in five additional AD case–control studies
from Flanders-Belgium (842 cases and 489 controls),
Finland (560 cases and 623 controls), Germany (728 cases
and 961 controls), Italy (1846 cases and 904 controls) and
Spain (1117 cases and 1084 controls) (Supplementary
Tables 3 and 4). The same common haplotypes were
inferred from the six SNPs in the two loci, with the
exception of the AGT haplotype in Chromosome 10p13
in the Italian population (frequency < 0.01 in controls)
(Supplementary Table 5 and 6).
In a combined analysis of the five replication data
sets, the overall difference in haplotype distribution
for the 6p21 locus was not significant between AD
cases and controls (P= 0.13) and the GGT haplotype
was not associated with AD risk (OR: 0.89; 95% CI:
(0.74–1.08); P= 0.23 after adjustment for age and
gender). We therefore considered that the haplotype
association in this locus was not confirmed (see
Supplementary Table 5).
Conversely, an overall significant difference in
haplotype distribution between AD cases and controls
was observed at the 10p13 locus in the replication
sample (P= 4.3 102 after adjustment for age, gender
and country) and the AAC haplotype was asso-
ciated with increased AD risk in the five data
sets meta-analysis (OR: 1.55; 95% CI: (1.19–2.00);
P= 9.2104 after adjustment for age and gender).
When the seven data sets (EADI1, GERAD1 and the
follow-up studies) were analyzed together, the AAC
haplotype had a meta-analysed OR of 1.68 (95% CI:
(1.43–1.96); P= 1.1 1010 adjusted for age and
gender) when compared with the most frequent GGC
haplotype, with no evidence of heterogeneity across
the seven countries (P= 0.92) (Figure 1). Among the
whole sample, nine cases were homozygous for the
AAC haplotype versus only five controls (OR: 2.85;
95% CI: (0.88–9.76); P= 0.09 with Yates correction),
which is consistent with a dose-dependent effect of
the AAC haplotype.
Importantly, none of the individual SNPs were
associated with AD risk in the total sample with a
P value lower than 105. The best meta-analysed
SNP was rs2446581 (OR: 1.15; 95% CI: (1.08–1.24);
P= 2.1105 after adjustment for age and gender;
Supplementary Table 7). The hypothesis that the
rs2446581 could solely explain the association
observed with the 10p13 haplotypes was rejected by
use of the likelihood ratio test (P= 9.1 107).
We also tested whether this haplotype asso-
ciation might be explained by one or more untyped
SNPs located nearby the genotyped SNPs. Genotypes
for 7 704 555 million SNPs with a MAFX0.01
were imputed from the French GWA data by using
the 1000 genome dataset (http://www.1000genomes.
org/). None of the single SNPs imputed at this locus
(n= 2538) showed stronger evidence of asso-
ciation with the AD risk than the haplotypes ini-
tially identified (Supplementary Figure 1). The 10p13
haplotype region appeared to be fully included
Figure 1 Haplotypic Odd ratios (ORs) for Alzheimer’s disease (AD) risk with the AAC haplotype derived from rs7081208,
rs2446581, rs17314229 at Chromosome 10p13 in seven independent European populations.
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within the FERM domain containing 4A (FRMD4A)
gene, as indicated by the linkage disequilibrium map
of this locus of interest (Figure 2).
We finally explored how FRMD4A might be
involved in the AD process. According to a recent
report, the FRMD4A gene was described to interact
with Arf6.24 As this latter protein was reported to
control APP processing,25 we postulated that the
FRMD4A locus could be associated with endopheno-
types susceptible to reflect modulation of the APP
metabolism. We accordingly analyzed association of
the FRMD4A locus with Ab peptide plasma concen-
trations in three independent populations of non-
demented individuals (n= 2579) (Supplementary
Table 2) for which FRMD4A imputed SNPs, Ab140
and Ab142 plasma concentrations were available.
Strong associations were observed between several
FRMD4A SNPs and Ab142/Ab140 (nine SNPs reach-
ing a significant level after Bonferroni correction,
P= 3.4105 for 1486 SNPs, Figure 3). The best signal
was obtained for rs7921545 (meta-analysed z-score b
coefficient: 0.12, CI: 95% (0.07–0.017); P= 5.4107)
and was homogeneous between the three data sets
(P for heterogeneity = 3.7 101, Supplementary
Figure 2). Of note, rs2446581 showed nominal asso-
ciation with Ab142/Ab140 (P= 3.1102, see Supple-
mentary Figure 2). Furthermore, only nominal
associations between FRMD4A SNPs, Ab140 or Ab142
were detected (see Supplementary Figure 3).
Discussion
From a specific haplotype-based GWAS approach,
we were able to detect a new genetic susceptibility
factor for AD that could not be identified through
usual GWAS analyses. Owing to the high number
of association tests performed in this GWHA study
(37 330 050, not all of which were independent), a
robust replication strategy was necessary. Our three-
step approach was thus particularly conservative
and we cannot rule out the possibility that we failed
to identify other haplotype-based loci associated
with AD risk. Nonetheless, our GWHA immediately
identified two potential AD susceptibility loci among
which the 10p13 locus showed an AAC haplotype
that was strongly and consistently associated with
AD risk in seven independent European populations.
Interestingly, this locus is included in the large
AD linkage region regularly identified on chromo-
some 10.26
Additional work will be necessary to determine
whether the AD risk-haplotype association indicates
an interaction between SNPs or whether they tag non-
genotyped, functional variants. However, our GWHA
study could have handled several of the inherent
limitations of GWAS. As the AAC haplotype is rare
(with a mean frequency of 2% in our Caucasian
populations), our work suggests the possibility that
rare variants may be responsible for the signal
detected within the FRMD4A gene. This might
explain why the locus was not detected (i) in our
previous GWA studies based on single-SNPs ana-
lyses5–9 and (ii) through imputation, as SNPs with
low frequency and/or SNPs within specific regions
with low LD are poorly imputed even when using the
1000 genome data set (Figure 2). Furthermore, we
cannot rule out the possibility that the AAC haplo-
type tags insertion–deletion variants or copy-number
Figure 2 Linkage disequilibrium map in the FRMD4A locus and localization of the region defined by the rs7081208,
rs2446581 and rs17314229 at this locus (in bold).
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variations—neither of which is captured by imputa-
tion. Interestingly, several copy-number variations
within the FRMD4A locus have been described
(http://projects.tcag.ca/variation/).
Little is known about the function of the protein
encoded by FRMD4A in animal cells. It belongs to the
FERM super family, which includes ubiquitous com-
ponents of the cytocortex involved in cell structure,
transport and signalling functions.27 According to a
recent report, the FRMD4A gene product may regulate
epithelial polarity by interacting with Arf6 and the
PAR complex.24 Interestingly, several other lines of
evidence suggest that Arf6 modulates cell polarity in
various systems—including neurons. Arf6 reportedly
regulates dendritic branching in hippocampal neurons
and neurite outgrowth in PC12 cells.28,29 Finally, Arf6
was recently reported to control APP processing,27
suggesting that FRMD4A could also be implied in
this metabolism. This hypothesis is sustained by the
observation of an association of the FRMD4A locus
with plasma Ab142/Ab140, at once reinforcing the
plausibility of the association of this gene with AD risk
and its potential implication in a subtle control of the
APP metabolism. Unfortunately, as the SNPs defining
the AAC haplotype were only available by imputation
in the Rotterdam and CHS study, search for association
of the AAC haplotype with plasma Ab142/Ab140 was
not possible. Furthermore, it is important to keep in
mind that this result is difficult to interpret in terms of
AD pathophysiological process. First, it is not known
whether plasma Ab peptides reflect a dynamic equili-
brium between the brain, CSF and plasma compart-
ments.30–34 Second, the source of plasma Ab species is
not known and the Ab peptides’ physiological func-
tions are still not fully understood.35,36
However, taken as a whole, these data suggest that
FRMD4A could be a relevant candidate gene for AD
risk and the basis for another possible pathophysio-
logical pathway for AD.
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